UM-SCC-1 Squamous Carcinoma Cell Line

All UM-SCC cell lines were derived in the lab of Dr. Thomas Carey at the University of Michigan and are exclusively distributed by Merck KGaA, Darmstadt, Germany. Access to UM-SCC cells is limited solely to those officers, employees and students of PURCHASER’s institution who need access to perform research. PURCHASER may not distribute UM-SCC cells or derivatives to third parties. PURCHASER shall comply with all applicable laws in its use and handling of the Product and shall keep it under reasonable safe and secure conditions to prevent unauthorized use or access.
Subject to local law, this product is intended to be sold for internal in vitro research use only subject to terms and conditions found here: www.sigmaaldrich.com/restrictedcelluse. This product may not be: re-engineered or copied; used to make derivatives, modifications or functional equivalents; used to obtain patents or other IP claiming use of the product; used to develop, test, or manufacturer a commercial product; used as a component in a commercial product; resold or licensed; used in any clinical applications or trials; or used in humans. A license or limited commercial use agreement is required for use by any for-profit entity, use in services, and use in sponsored academic research. For information regarding any such use, please contact licensing@milliporesigma.com.



Head and neck squamous cell carcinoma (HNSCC) develops from the mucosal linings of the upper aerodigestive tract, comprising 1) the nasal cavity and paranasal sinuses, 2) the nasopharynx, 3) the hypopharynx, larynx, and trachea, and 4) the oral cavity and oropharynx. Squamous cell carcinoma (SCC) is the most frequent malignant tumor of the head and neck region. HNSCC is the sixth leading cancer by incidence worldwide. There are 500,000 new cases a year worldwide and two thirds occur in industrialized nations. It is caused by tobacco and alcohol consumption and infection with high-risk types of human papillomavirus (HPV). SCC often develops from preexisting dysplastic lesions. The five-year survival rate of patients with HNSCC is about 40-50%.

UM-SCC-1 is a unique head and neck squamous carcinoma cell line isolated from the tumor located on the floor of the mouth of a male patient. The cell line is negative for HPV-16 and for HLA-A2, a class I molecule of the major histocompatibility complex (MHC). The UM-SCC-1 cell line is 50% more invasive in vitro and displays a greater propensity for perineural and lymphatic invasion in vivo.

UM-SCC-1 was established at the University of Michigan (1) with written informed consent obtained from the patient and with the approval of the study by the Medical School Institutional Review Board.

Reference:


1) Carey, T., et al. (2012) Genotyping of 73 UM-SCC head and neck squamous cell carcinoma cell lines. Head Neck. 2010 April; 32(4): 417–426.

UM-SCC-1 cells should be stored in liquid nitrogen. The cells can be cultured for at least 10 passages after initial thawing without significantly affecting the cell marker expression and functionality.

• Each vial contains ≥ 1X10⁶ viable cells.
• Cells are tested by PCR and are negative for HPV-16, HPV-18, Hepatitis A, B, C and HIV-1 & 2 viruses.
• Cells are negatrive for mycoplasma contamination.
• Each lot of cells are genotyped by STR analysis to verify the unique identity of the cell line.

1) ≥1X10⁶ viable UM-SCC-1 Squamous Carcinoma Cells: (Catalog No. SCC070). Store in liquid nitrogen.